Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new
RésuméThis study assessed the utility of some novel inflammatory markers compared with traditional laboratory markers in patients with systemic lupus erythematosus [SLE]. In a cohort of 43 SLE patients [19 with inactive and 24 with active SLE] and 20 healthy controls, serial measures of soluble vascular cell adhesion molecule [sVCAM-1] were significantly associated with SLE disease activity, scored using the British Isles Lupus Assessment Group index. Inflammatory markers neopterin and soluble intercellular adhesion molecule [sICAM-1] appeared to be clinically useful for isolated assessments of disease activity. Both antibodies to double-stranded DNA [antidsDNA] and sVCAM-1 were relatively good markers of disease activity and could help to predict remission or monitor the therapeutic response in SLE
Elwy, M.A., Galal, Z.A. & Hasan, H.E. (2010). Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new. http://www.who.int/iris/handle/10665/117956
EMHJ - Eastern Mediterranean Health Journal, 16 (8), 893-900, 2010
MétadonnéesAfficher la fiche complète
Affichage des documents associés par titre, auteur, créateur et sujet.
Tazi, I.; Fehri, S.; Elghrari, K.; Ouazzani, T.; Benchemsi, N. (2009)We determined the prevalence of antibodies to Epstein-Barr virus [EBV] in 44 patients with systemic lupus erythematosus [SLE] and 44 healthy blood donors matched for sex and age as controls. Of the cases, 39 were women; mean age was 33 years. Four cases [9%] and 5 controls [11%] were positive for IgM anti-viral capsid antigen [VCA] [P = 0.9]. All the cases were positive for IgG anti-VCA compared with 91% of the controls [P = 0.12]. The mean immunity ratio for this antibody was 2.341 in cases and 1.873 in controls [P = 0.068]. Forty [91%] cases ...
Najim, R.A.; Farid, Y.Y.; Samad, T.A.; Shihab, S.A. (2005)The study was designed to determine the acetylator status in patients with systemic lupus erythematosus [SLE] and compare it to a matched group of healthy volunteers. Disease severity was determined using the revised American College of Rheumatology criteria for classification and the SLE disease activity index. After an overnight fast, each participant received a single oral dose of 100 mg dapsone. After 3 hours, plasma dapsone/monoacetyldapsone ratio was determined. In the control group, frequency of slow acetylators was 73.3%; frequency of ...